These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 19458053)
21. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663 [TBL] [Abstract][Full Text] [Related]
22. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214 [TBL] [Abstract][Full Text] [Related]
23. Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Provencio M; Camps C; Cobo M; De las Peñas R; Massuti B; Blanco R; Alberola V; Jimenez U; Delgado JR; Cardenal F; Tarón M; Ramírez JL; Sanchez A; Rosell R Cancer Chemother Pharmacol; 2012 Dec; 70(6):883-90. PubMed ID: 23053267 [TBL] [Abstract][Full Text] [Related]
24. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method. Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284 [TBL] [Abstract][Full Text] [Related]
25. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283 [TBL] [Abstract][Full Text] [Related]
26. Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy. Tan X; Wu Q; Cai Y; Zhao X; Wang S; Gao Z; Yang Y; Li X; Qian J; Wang J; Su B; Chen H; Han B; Jiang G; Lu D Clin Lung Cancer; 2014 Jan; 15(1):67-78.e12. PubMed ID: 24220096 [TBL] [Abstract][Full Text] [Related]
27. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients. Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224 [TBL] [Abstract][Full Text] [Related]
28. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population. Gan Y; Li XR; Chen DJ; Wu JH Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245 [TBL] [Abstract][Full Text] [Related]
29. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547 [TBL] [Abstract][Full Text] [Related]
30. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy. Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006 [TBL] [Abstract][Full Text] [Related]
31. Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Gu S; Wu Q; Zhao X; Wu W; Gao Z; Tan X; Qian J; Chen H; Xie Y; Jin L; Han B; Lu D Cancer Sci; 2012 Aug; 103(8):1451-9. PubMed ID: 22568453 [TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. Zhang L; Ma W; Li Y; Wu J; Shi GY Genet Mol Res; 2014 Jan; 13(1):228-36. PubMed ID: 24446315 [TBL] [Abstract][Full Text] [Related]
33. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Liang G; Xing D; Miao X; Tan W; Yu C; Lu W; Lin D Int J Cancer; 2003 Jul; 105(5):669-73. PubMed ID: 12740916 [TBL] [Abstract][Full Text] [Related]
34. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy. Zhou F; Gao G; Ren S; Li X; He Y; Zhou C PLoS One; 2013; 8(4):e61585. PubMed ID: 23620771 [TBL] [Abstract][Full Text] [Related]
35. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs. Li XD; Han JC; Zhang YJ; Li HB; Wu XY Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713 [TBL] [Abstract][Full Text] [Related]
36. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer. Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940 [TBL] [Abstract][Full Text] [Related]
37. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637 [TBL] [Abstract][Full Text] [Related]
38. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Qian J; Qu HQ; Yang L; Yin M; Wang Q; Gu S; Wu Q; Zhao X; Wu W; Wu J; Tan X; Chen W; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L Oncologist; 2012; 17(12):1551-61. PubMed ID: 22843554 [TBL] [Abstract][Full Text] [Related]
39. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009 [TBL] [Abstract][Full Text] [Related]
40. Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Lai JI; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS Cancer Sci; 2009 Jul; 100(7):1261-6. PubMed ID: 19432884 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]